TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial

BACKGROUND: TRC150094, a novel mitochondrial modulator, reduces insulin resistance and is expected to improve the trinity of dysglycemia, dyslipidemia, and hypertension. In this multi-dose phase-2 study, we evaluated the safety and efficacy of TRC150094 in diabetic subjects with dyslipidemia receivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Deepa, GJ, Prashant, Ghosh, Shohini, Mohanan, Anookh, Joshi, Shashank, Mohan, Viswanathan, Chowdhury, Subhankar, Dutt, Chaitanya, Tandon, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887612/
https://www.ncbi.nlm.nih.gov/pubmed/35241920
http://dx.doi.org/10.2147/DMSO.S330515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887612/
https://www.ncbi.nlm.nih.gov/pubmed/35241920
http://dx.doi.org/10.2147/DMSO.S330515

Ejemplares similares